Inventurus Knowledge Solutions Ltd (IKS) Q1 FY27 Earnings Call: Pro Forma EBITDA Margin at 26-27%, Revenue Crosses Rs. 890 Cr

Inventurus Knowledge Solutions Ltd held its Q1 FY27 earnings call on August 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue crosses Rs.890 crore; adjusted EBITDA margin holds at 35%

• Q1 FY 2026-2027 revenue of Rs.893 crore — up 21% YoY and 12% in constant currency; forex impact was neutral versus Q4 FY 2025-2026.
• Reported EBITDA of Rs.294 crore (33% margin) — adjusted for ~Rs.20 crore of one-time TrueBridge acquisition costs, EBITDA was Rs.314 crore (~35%), in line with the 35% adjusted margin of Q4 FY 2025-2026.
• Reported net profit of Rs.194 crore (22% margin) — PAT of Rs.193 crore was up 28% YoY; EPS grew 30% YoY in Q1 FY 2026-2027.
• ROE of 26% in Q1 FY 2026-2027 — declined QoQ on one-time acquisition costs and the mark-to-market uplift on the Abridge strategic investment; the revaluation flows through OCI with no P&L impact.
• Legacy IKS tax rate of 22.4% in Q1 FY 2026-2027 — expected to stay in the 22-23% range for the rest of FY 2026-2027; pro forma combined-entity tax guidance is slated for Q2 FY 2026-2027.
• TTM EBITDA (standalone, pre-TrueBridge) of Rs.1,148 crore as of Jun 30, 2026 — up from Rs.647 crore as of Sep 30, 2024 (~40% CAGR); adjusted EBITDA yield was 90% in Q1 FY 2026-2027.

$68 million EBITDA asset at ~8.1x on a lower revenue base

• ~$550 million paid for ~$68 million of TrueBridge EBITDA (~8.1x) — won via a banker-run auction after an ~18-month thematic corp-dev search; TrueBridge holds 30%+ market share as one of two dominant EHR vendors in the rural market.
• TrueBridge annualized revenue base cut to ~$300 million from a prior ~$340 million expectation — reflecting more conservative revenue recognition (~$2-3 million/quarter), elimination of two unprofitable services (~$8 million/quarter) and anticipated customer discounts (~$2-3 million/quarter).
• TrueBridge EBITDA is unchanged at ~$68 million (~Rs.650 crore) — the revenue rationalization was "not foreseen before the acquisition", per CEO Sachin Gupta.
• Combined business run-rate of ~$688 million revenue and ~Rs.1,800 crore EBITDA — legacy IKS at ~$388 million annualized (~Rs.1,150 crore EBITDA) plus TrueBridge at ~$300 million annualized (~Rs.650 crore EBITDA).
• Pro forma EBITDA margin expected to drop to 26-27% post-consolidation — TrueBridge closed on July 10, 2026 and is not reflected in Q1 FY 2026-2027 reported numbers.
• Acquisition expected to be EPS accretive for FY 2026-2027 — "perhaps even a bit more EPS accretive than we had imagined", per CEO Sachin Gupta; ~Rs.20 crore of integration costs hit Q1 FY 2026-2027, with similar expenses expected in Q2 FY 2026-2027.

New health-system wins and five-year lock-in deals

• Key Q1 FY 2026-2027 client wins — a large California health system (Epic partnership), a national musculoskeletal leader, an expansion with Advocate Health (a top-5 US health system) and StrideCare (vascular/vein surgery).
• Recent deals carry 5-year lock-in periods at "very healthy" prices — management acknowledged competitive intensity is increasing even as it signs these long-tenure contracts.
• Top-10 and top-5 customer revenue grew healthily in Q1 FY 2026-2027 — contribution held flat QoQ; average customer vintage is ~6 years for top-10 and ~7 years for top-5 customers.
• Rural + community hospital TAM estimated at $260 billion+ — with outsourcing penetration of ~$35 billion growing ~12%; management also cited a broader $200+ billion TAM growing 8% (period unspecified).
• Cross-sell land-and-expand is starting to work in large health systems on the legacy IKS side — management "sees a healthy outlook for the next 4-5 years".

Three SLM architectures target 60% lower token utilization

• AI strategy deploys three SLM approaches — standalone SLMs, SLMs distilled from LLMs, and a hierarchical SLM+LLM architecture; explainability is delivered via knowledge graphs from the ERI acquisition.
• Aspirational target to reduce token utilization by 60% vs traditional LLMs — a metric that will emerge over time (period unspecified), per CEO Sachin Gupta.
• Patent approved for the AAW model — predicts patient no-show and propensity to pay; a case study with Axia Women's Health delivered $12 million in cash impact through optimized coding.
• CEO Sachin Gupta acknowledged Abridge's move from an AI scribe to a pre-to-post visit platform — while noting ~30 other vendors are pursuing similar point-solution-to-platform evolutions.
• The Abridge strategic investment was marked higher in Q1 FY 2026-2027 — the revaluation goes through OCI, so there is no P&L impact, per CFO Nitya Balasubramanian.

People cost up just 4.2% against 12% constant-currency growth